<p>Sex chromosome aneuploidy (SCA) syndromes are defined by the presence of a sex chromosome complement other than the typical XX for females and XY for males. SCAs are collectively common and increase risks for diverse immune, metabolic, and neuropsychiatric illnesses. Understanding genome-wide transcriptomic changes in SCAs is critical for clarifying the biological underpinnings of their clinical phenotypes. Assessments of sex chromosome dosage (SCD) effects on gene expression in humans have often been confined to the use of a few SCA subtypes (e.g., XO or XXY) - precluding analysis of the same SCD change in different contexts. Our study used RNA-seq data from lymphoblastoid cell lines in 197 individuals representing diverse SCA karyotypes (49 XX, 24 XXX, 39 XY, 39 XXY, 23 XXYY, 23 XYY) to assess expression changes for 25,075 genes in multiple pairwise SCD group comparisons. The <a href="https://www.pnas.org/doi/10.1073/pnas.2218478120">paper</a> reporting our findings has been cited below.</p>

Sex Chromosome Aneuploidy Effects on Human Gene Expression

Sex Chromosome Aberrations study with RNA-Seq data on dbGaP (197 participants)

Sex Chromosome Aneuploidy Effects on Human Gene Expression

Description

Applying For Access

Summary